Real-Life Effectiveness and Tolerance of Upadacitinib for Severe Atopic Dermatitis in Adolescents and Adults

Funding

No funding or sponsorship was received for this study or publication of this article. The Rapid Service and Open Access Fee were funded by the authors.

Medical Writing and Editorial Assistance

We thank Dr. Mariana Andrade, MD (Andrade-Evrard SPRL), who provided editorial assistance.

Author Contributions

Axel De Greef: Conceptualization, Methodology, Validation, Formal analysis, Investigation, Resources, Data Curation, Writing—Original Draft, Visualization; Pierre-Dominique Ghislain: Data Curation, Investigation, Writing—Review & Editing, Supervision; Laurence de Montjoye: Investigation, Data Curation; Marie Baeck: Conceptualization, Methodology, Validation, Formal analysis, Investigation, Resources, Data Curation, Writing—Review & Editing, Supervision.

Disclosures

Pierre-Dominique Ghislain discloses his past participation as an investigator and as a scientific advisor for AbbVie. Pierre-Dominique Ghislain and Marie Baeck have previously participated as speakers in events sponsored by AbbVie. None of the authors has scientific or financial conflicts of interests to declare in the current reported study.

Compliance with Ethics Guidelines

This study and data collection were conducted with the approval of the hospital and faculty institutional review board (Commission d’Ethique Biomédicale Hospitalo-Facultaire) of Université catholique de Louvain (UCLouvain), Belgium (registration number B4032020000018). This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments. The patients in this manuscript have given written informed consent to participate and for publication of their case details.

Data Availability

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

留言 (0)

沒有登入
gif